Bunazosin
Chemical compound
- none
- 1-(4-(4-amino-6,7-dimethoxyquinazolin-2-yl)-1,4-diazepan-1-yl)butan-1-one
- 80755-51-7
- 2472
- 2378
Y
- 9UUW4V7G2H
- ChEMBL188185 Y
- DTXSID7022700
- Interactive image
- CCCC(=O)N1CCCN(CC1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC
InChI
- InChI=1S/C19H27N5O3/c1-4-6-17(25)23-7-5-8-24(10-9-23)19-21-14-12-16(27-3)15(26-2)11-13(14)18(20)22-19/h11-12H,4-10H2,1-3H3,(H2,20,21,22)Y
- Key:RHLJLALHBZGAFM-UHFFFAOYSA-NY
Bunazosin (INN) is an α1-adrenergic receptor antagonist.[1] Bunazosin was initially developed to treat benign prostatic hyperplasia (BPH). It has been approved in Japan in a topical form to treat glaucoma. The mechanism of action is a reduction of aqueous outflow through the uveoscleral pathway resulting in lowering the intraocular pressure. It also may act to improve blood flow to the ocular nerve. Systemic Alpha-1 adrenergic receptor antagonists have been implicated in Intraoperative Floppy Iris Syndrome (IFIS). Bunazosin potentially could have the same effect but there has been no research to substantiate this as a risk for cataract surgery.
References
- ^ Weidinger G (November 1995). "Pharmacokinetic and pharmacodynamic properties and therapeutic use of bunazosin in hypertension. A review". Arzneimittel-Forschung. 45 (11): 1166–71. PMID 8929232.
- v
- t
- e
Adrenergic receptor modulators
- See also: Receptor/signaling modulators
- Dopaminergics
- Serotonergics
- Monoamine reuptake inhibitors
- Monoamine releasing agents
- Monoamine metabolism modulators
- Monoamine neurotoxins
 | This antihypertensive-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
